{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:44:44Z","timestamp":1790844284757,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The disease shift of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL), so-called Richter transformation (RT), is a catastrophic clinical event. Rarely, survival can outperform expectations and accurate prognostication for patients may affect therapeutic choices. To date, prognosis has relied on readily available factors such as TP53 disruption, previous CLL treatment status, and performance score. Recently, a shared clonality assessment by immunoglobulin heavy-chain variable region gene (IgHV) sequencing of the CLL and RT has been considered therapeutically relevant, but this is infrequently performed. We performed a systematic review of peer-reviewed manuscripts where outcomes in relation to clonal relatedness and lack thereof (clonally related and clonally unrelated RT-DLBCL) were examined. Fifteen manuscripts that included 336 patients were found, of which 6 compared survival outcomes between the 2 groups in a statistically meaningful way. Two analyses showed no difference in survival outcomes with 4 studies reporting a significantly poorer prognosis with clonally related RT-DLBCL. In 2 of these studies, the baseline characteristics of clonally related and clonally unrelated groups were compared and the clonally related cases were enriched for underlying CLL, which was TP53 disrupted, IgHV unmutated, more heavily pretreated, and exhibiting stereotyped B-cell receptor VH CDR3 and RT-DLBCL, which was MYD88 wild type. We demonstrate that although clonal relatedness of the underlying CLL confers a poorer survival, this is not demonstrated in any study to be independent of other well-described clinical and genomic variables known to influence outcomes in RT-DLBCL. Further independent validation of this prognostic factor is required to help guide universal adoption into clinical practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015594","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:02:34Z","timestamp":1742846554000},"page":"2773-2780","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0767","authenticated-orcid":false,"given":"Aisling","family":"Barrett","sequence":"first","affiliation":[{"name":"Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Harris","sequence":"additional","affiliation":[{"name":"Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2025061008221205000_bib1","doi-asserted-by":"crossref","first-page":"101163","DOI":"10.1016\/j.blre.2023.101163","article-title":"Richter's transformation: transforming the clinical landscape","volume":"64","author":"Barrett","year":"2024","journal-title":"Blood Rev"},{"issue":"6","key":"2025061008221205000_bib2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"issue":"10","key":"2025061008221205000_bib3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2025061008221205000_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2008.07166.x","article-title":"Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome","volume":"142","author":"Rossi","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2025061008221205000_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"2025061008221205000_bib6","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025061008221205000_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"15","key":"2025061008221205000_bib8","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025061008221205000_bib9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2025061008221205000_bib10","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2025061008221205000_bib11","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European research initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"2025061008221205000_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.22.01028","article-title":"Emerging therapies for the management of Richter transformation","volume":"41","author":"Smyth","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025061008221205000_bib13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/bjh.17882","article-title":"Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology good practice paper","volume":"196","author":"Eyre","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"2025061008221205000_bib14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1046\/j.1440-1827.2000.01094.x","article-title":"Analysis of the immunoglobulin heavy chain gene of secondary diffuse large B-cell lymphoma that subsequently developed in four cases with B-cell chronic lymphocytic leukemia or lymphoplasmacytoid lymphoma (Richter syndrome)","volume":"50","author":"Nakamura","year":"2000","journal-title":"Pathol Int"},{"issue":"10","key":"2025061008221205000_bib15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2025061008221205000_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2025061008221205000_bib17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hon.2502","article-title":"Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia","volume":"36","author":"Innocenti","year":"2018","journal-title":"Hematol Oncol"},{"issue":"2","key":"2025061008221205000_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"2025061008221205000_bib19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"19","key":"2025061008221205000_bib20","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"2025061008221205000_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cancergen.2021.10.003","article-title":"Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation","volume":"260-261","author":"Hess","year":"2022","journal-title":"Cancer Genet"},{"issue":"1","key":"2025061008221205000_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pathol.2021.04.008","article-title":"Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax","volume":"54","author":"G\u00e1ng\u00f3","year":"2022","journal-title":"Pathology"},{"issue":"1","key":"2025061008221205000_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-022-34642-6","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Bros\u00e9us","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"2025061008221205000_bib24","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda","year":"2024","journal-title":"Lancet Haematol"},{"issue":"10","key":"2025061008221205000_bib25","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"2025061008221205000_bib26","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/ijc.26322","article-title":"Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis","volume":"130","author":"Rossi","year":"2012","journal-title":"Int J Cancer"},{"key":"2025061008221205000_bib27","article-title":"","volume":"13","author":"Riccardo Moia","year":"2024","journal-title":"European Haematology Association"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2773\/2377227\/blooda_adv-2024-015594-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2773\/2377227\/blooda_adv-2024-015594-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:22:22Z","timestamp":1749558142000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/11\/2773\/536294\/Clonal-relatedness-as-a-prognostic-marker-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015594","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,10]]},"published":{"date-parts":[[2025,5,30]]}}}